CARM (CARISMA Therapeutics) ROE % Adjusted to Book Value: Negative Equity% (As of Sep. 2025)


What is CARISMA Therapeutics ROE % Adjusted to Book Value?

CARISMA Therapeutics CARM -27.16% ROE % Adjusted to Book Value is Negative Equity% as of Sep. 2025. The stock has 3 warning signs investors should review.

CARISMA Therapeutics's ROE % for the quarter that ended in Sep. 2025 was Negative Equity. CARISMA Therapeutics's PB Ratio for the quarter that ended in Sep. 2025 was N/A. CARISMA Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 was Negative Equity.

CARISMA Therapeutics ROE % Adjusted to Book Value Related Terms

CARISMA Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for CARISMA Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics ROE % Adjusted to Book Value Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
0.00 0.00 0.00 0.00 0.00

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 Negative Equity

CARM vs SCPX, CYTOF, CNBX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, CARISMA Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's ROE % Adjusted to Book Value falls into.


CARISMA Therapeutics ROE % Adjusted to Book Value Calculation

CARISMA Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

CARISMA Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of Negative Equity% mean?
CARISMA Therapeutics (CARM) has a ROE % Adjusted to Book Value of Negative Equity% as of Sep. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CARISMA Therapeutics and its competitors.
Is CARISMA Therapeutics' ROE % Adjusted to Book Value too high?
CARISMA Therapeutics' current ROE % Adjusted to Book Value is Negative Equity%.
How does CARISMA Therapeutics' ROE % Adjusted to Book Value compare to SCPX and CYTOF?
CARISMA Therapeutics' ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on CARISMA Therapeutics and its competitors. CARISMA Therapeutics's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current ROE % Adjusted to Book Value is Negative Equity%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current ROE % Adjusted to Book Value is Negative Equity% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARISMA Therapeutics Business Description

Address 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.